State Street SPDR S&P Biotech ETF
458 hedge funds and large institutions have $7.43B invested in State Street SPDR S&P Biotech ETF in 2020 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 150 increasing their positions, 148 reducing their positions, and 78 closing their positions.
53.4% more ownership
Funds ownership: 118.36% → 171.76% (+53%)
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
18% more capital invested
Capital invested by funds: $6.3B → $7.43B (+$1.13B)
1% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 148
3% less funds holding
Funds holding: 474 → 458 (-16)
12% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 78
61% less call options, than puts
Call options by funds: $650M | Put options by funds: $1.68B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$864M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$665M |
| 3 |
Goldman Sachs
New York
|
+$589M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$307M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$226M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$268M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$208M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$118M |
| 4 |
Two Sigma Investments
New York
|
-$82.1M |
| 5 |
CAC
Cowen and Company
New York
|
-$35.4M |
XBI Hedge Fund Activity: Q1 2020 in Review
458 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2020, worth a combined $7.43B — up 18% from $6.3B a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of XBI and 69 opened new positions — a net loss of 9 holders — while 148 trimmed existing stakes and 150 added.
The largest buyer was JP Morgan Chase, adding an estimated $864M. The largest seller was Bank of Nova Scotia, cutting an estimated $268M.
- 458 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2020, down from 474 in Q4 2019.
- Funds reported $7.43B of State Street SPDR S&P Biotech ETF stock for Q1 2020, up 18% quarter-over-quarter.
- 69 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2020 and 78 closed out, a net change of -9 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2020 was JP Morgan Chase, an estimated $864M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2020 was Bank of Nova Scotia, an estimated $268M sold.
Based on aggregated 13F filings for Q1 2020.